VIRI
vs
S&P 500
VIRI
S&P 500
Over the past 12 months, VIRI has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +18% growth.
Stocks Performance
VIRI vs S&P 500
Performance Gap
VIRI vs S&P 500
Performance By Year
VIRI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Virios Therapeutics Inc
Glance View
Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. The company is headquartered in Alpharetta, Georgia and currently employs 5 full-time employees. The company went IPO on 2020-12-17. Its lead development candidate is IMC-1, which is a fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication. Its HSV-1 root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatigue syndrome and functional somatic syndrome. The firm is developing its initial candidate, IMC-1, for people who are suffering from fibromyalgia.
